Clinical Trials Browser

Phase 2 × INDUSTRY × Patient Preference × Clear all

NCT06101134 2025-04-14

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2 Active not recruiting

Melanoma, Neoplasm Metastasis, Patient Preference